Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease

Archives of Neurology

Volumn 57, Issue 6, 2000, Pages 831-836

  Halliday, Glenda M ^a   Shepherd, Claire E ^a   McCann, Heather ^a   Reid, Wayne G J ^b   Grayson, David A ^b   Broe, G Anthony ^b   Kril, Jillian J ^b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 0034047831     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.6.831     Document Type: Article

References (46)

1. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998;33:371-378.
2. Pasinetti GL. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res. 1998;54:1-6.
3. Gahtan E, Overmier JB. Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Neurosci Biobehav Rev. 1999;23: 615-633.
4. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
5. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626-632.
6. Karplus TM, Saag KG. Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect? Drug Safety. 1998;19:427-433.
7. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988;9:339-349.
8. Mackenzie I, Hao C, Munoz D. Role of microglia in senile plaque formation. Neurobiol Aging. 1995;16:797-804.
9. Sheng JG, Mrak RE, Griffin ST. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged and phagocytic forms. Acta Neuropathol (Berl). 1997;94:1-5.
10. Kalaria RN, Cohen DL, Premkumar DRD. Cellular aspects of the inflammatory response in Alzheimer's disease. Neurodegeneration. 1996;5:497-503.
11. Broe GA, Henderson AS, Creasey H, et al. A case control study of Alzheimer's disease in Australia. Neurology. 1990;40:1698-1707.
12. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
13. Mirra S, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
14. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol. 1998;24:195-201.
15. Harding AJ, Kril JJ, Halliday GM. Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathol. 2000;99: 199-208
16. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(suppl 4):S1-S2.
17. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol. 1998;11:45-49.
18. Grau AJ. Infection, inflammation, and cerebrovascular ischemia. Neurology. 1997; 49(suppl 4):S47-S51.
19. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol. 1998;56:149-171.
20. Mattiace LA, Davies P, Dickson DW. Detection of HLA-DR microglia in the human brain is a function of both clinical and technical factors. Am J Pathol. 1990; 136:1101-1114.
21. Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990:31:545-548.
22. Shepherd CE, Thiel E, McCann H, Harding AJ, Halliday GM. Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch Neurol. 2000; 57:817-822.
23. Gundersen HJG, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988;96:379-394.
24. Reid W, Broe GA, Creasey H, et al. Age at onset and patterns of neuropsychological impairment in mild early-stage Alzheimer disease: a study of a community-based population. Arch Neurol. 1996;53:1056-1061.
25. Henderson AS, Jorm AF, Korten AE, et al. Environmental risk factors for Alzheimer's disease: their relationship to age of onset and familial or sporadic types. Psychol Med. 1992;22:429-436.
26. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986-990.
27. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195-200.
28. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 1989;77:569-575.
29. Dickson DW, Lee SC, Mattiace LA, Yen S-HC, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 1993;7:75-83.
30. Carpenter AF, Carpenter PW, Markesbery WR. Morphometric analysis of microglia in Alzheimer's disease. J Neuropathol Exp Neurol. 1993;52:601-608.
31. Uchihara T, Duyckaerts C, He Y, et al. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci Lett. 1995;195:5-8.
32. Roe MT, Dawson DV, Hulete CM, Einstein G, Grain BJ. Microglia are not exclusively associated with plaque-rich regions of the dentate gyrus in Alzheimer's disease. J Neuropathol Exp Neurol. 1996;55:366-371.
33. Jefferies WA, Food MR, Gabathuler R, et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 1996;712:122-126.
34. Lue LF, Brachova L, Civin H, Rogers J. Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083-1088.
35. Maat-Schieman M, van Duinen S, Rozemuller A, Haan J, Roos R. Association of vascular amyloid β and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:273-284
36. McDowell I, Hill G, Lindsay J, et al. The Canadian study of health and aging: risk factors for Alzheimer's disease in Canada. Neurology. 1994;44:2073-2080.
37. Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? Neurology. 1998;50:374-379.
38. Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry. 1997;12: 926-930.
39. Hershkowitz M, Adunsky A. Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct dementia patients. Neurobiol Aging. 1996; 17:865-868,
40. Zubenko G, Winwood E, Jacobs B, et al. Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. Am J Psychiatry. 1999;156:50-57.
41. Smith CCT. Stimulated release of the β-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci Lett. 1997;235:157-159.
42. Li OX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab Invest. 1998;78:461-469.
43. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
44. Crawford F, Suo Z, Fang C, Mullan M. Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp Neurol. 1998;150:159-168.
45. Paris D, Town T, Parker TA, Humphrey J, Mullan M. Isoform specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's β-amyloid peptide. Neurosci Lett. 1998;256:73-76.
46. Suo Z, Humphrey J, Kundtz A, et al. Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett. 1998;257:77-80.